Benlhachemi Sara, Abouqal Redouane, Coleman Nicholas, Murray Matthew Jonathan, Khattab Mohammed, El Fahime Elmostafa
Laboratory of Genomics and Molecular Epidemiology of Genetic Diseases (GE2MG). Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco.
Molecular Biology and Functional Genomics Platform, National Center for Scientific and Technical Research, Rabat, Morocco.
Noncoding RNA Res. 2023 May 26;8(3):413-425. doi: 10.1016/j.ncrna.2023.05.007. eCollection 2023 Sep.
Wilms tumour (WT) is caused by aberrant embryonic kidney development and associated with dysregulated expression of short, non-protein-coding RNAs termed microRNAs (miRNAs). At present, there is no reliable circulating biomarker of WT, and this remains an urgent unmet clinical need. Such biomarkers may assist diagnosis, subtyping/prognostication, and disease-monitoring. Here, we established the list of dysregulated circulating miRNAs in WT from the existing published literature.
Regardless of publication date, PubMed, Scopus, Web-of-Science, and Wiley online library databases were searched for English/French studies on WT circulating miRNAs. The PRISMA-compliant search was registered in PROSPERO. The QUADAS tool measured retained article quality. The meta-analysis assessed the sensitivity and specificity of miRNAs for WT diagnosis.
Qualitative analysis included 280 samples (172 WT patients; 108 healthy controls) from five of 450 published articles. The study uncovered 301 dysregulated miRNAs (144 up-regulated, 143 down-regulated, 14 conflicting). The pooled sensitivity, specificity, and AUC of the 49 significantly dysregulated microRNAs from two studies was 0.67 [0.62; 0.73], 0.95 [0.92; 0.96] and 0.77 [0.73; 0.81] respectively, indicating a stronger diagnostic potential for WT.
Circulating miRNAs show promise for WT diagnosis and prognosis. More research is needed to confirm these findings and determine associations with tumour stage/subtype.
CRD42022301597.
肾母细胞瘤(WT)由胚胎肾发育异常引起,与一类称为微小RNA(miRNA)的短链非蛋白质编码RNA的表达失调有关。目前,尚无可靠的WT循环生物标志物,这仍是临床亟待满足的需求。此类生物标志物可能有助于诊断、亚型分类/预后评估及疾病监测。在此,我们从现有已发表文献中确定了WT中表达失调的循环miRNA列表。
无论发表日期如何,在PubMed、Scopus、Web of Science和Wiley在线图书馆数据库中搜索关于WT循环miRNA的英文/法文研究。符合PRISMA标准的检索已在PROSPERO中注册。QUADAS工具评估纳入文章的质量。荟萃分析评估miRNA对WT诊断的敏感性和特异性。
定性分析纳入了450篇已发表文章中5篇的280个样本(172例WT患者;108例健康对照)。该研究发现了301个表达失调的miRNA(144个上调,143个下调,14个结果相互矛盾)。两项研究中49个显著表达失调的微小RNA的合并敏感性、特异性和AUC分别为0.67[0.62;0.73]、0.95[0.92;0.96]和0.77[0.73;0.81],表明其对WT具有更强的诊断潜力。
循环miRNA在WT诊断和预后评估方面显示出前景。需要更多研究来证实这些发现并确定与肿瘤分期/亚型的关联。
PROSPERO注册号:CRD42022301597。